Table 1.
Patients characteristics according to induction treatment.
| Patients Characteristics and Mutations | All patients, N = 221 |
ICE, N = 117 |
sHD, N = 104 |
p |
|---|---|---|---|---|
| Median age, at diagnosis (range) | 52.5 (19.8–74.8) | 54.4 (23.6–74.8) | 49.5 (19.8–72.2) | 0.0324 |
| ≤60 years | 166 (75.1) | 81 (69.2) | 85 (81.7) | 0.0319 |
| >60 years | 55 (24.9) | 36 (30.8) | 19 (18.3) | |
| Sex | 0.1765 | |||
| Female | 119 (53.8) | 58 (49.6) | 61 (58.7) | |
| Male | 102 (46.2) | 59 (50.4) | 43 (41.3) | |
| AML category | 0.0463 | |||
| Non de novo | 26 (11.8) | 9 (7.7) | 17 (16.3) | |
| De novo | 195 (88.2) | 108 (92.3) | 87 (83.7) | |
| ECOG PS | 0.4556 | |||
| 0-1 | 201 (91) | 108 (92.3) | 93 (89.4) | |
| 2-3 | 20 (9) | 9 (7.7) | 11 (10.6) | |
| Hepatomegaly | 17 (7.7) | 8 (6.8) | 9 (8.7) | 0.6130 |
| Splenomegaly | 20 (9) | 9 (7.7) | 11 (10.6) | 0.4556 |
| Extramedullary involvement | 34 (15.4) | 16 (13.7) | 18 (17.3) | 0.4550 |
| WBC count (×109/L) | 0.3677 | |||
| ≤50 | 155 (70.1) | 79 (67.5) | 76 (73.1) | |
| >50 | 66 (29.9) | 38 (32.5) | 28 (26.9) | |
| Hemoglobin (g/dL) | 9.5 (4.3–14.1) | 9.5 (5.1–14.1) | 9.5 (4.3–13.9) | 0.9144 |
| Platelets(×109/L) | 59 (5–815) | 64 (5–815) | 57.5 (8–513) | 0.8752 |
| Bone marrow blast cells, % | 80 (0–100) | 83 (10–100) | 80 (0–100) | 0.4519 |
| Peripheral blood blasts cells, % | 52 (0–100) | 50 (0–100) | 55.5 (0–100) | 0.6909 |
| Consolidation | 0.3276 | |||
| No alloHSCT | 119 (67.9) | 60 (59.4) | 59 (66.3) | |
| alloHSCT | 71 (32.1) | 41 (40.6) | 30 (33.7) | |
| FLT3 wt., NPM1 wt | 90/216 (41.7) | 42/112 (37.5) | 48/104 (46.2) | 0.1974 |
| FLT3-ITD low ratio, NPM1 wt | 6/221 (2.7) | 6/117 (5.1) | 0/104 (0) | 0.0307 |
| FLT3-ITD high ratio, NPM1 wt | 8/221 (3.6) | 4/117 (3.4) | 4/104 (3.8) | 1.0000 |
| FLT3 wt, NPM1 + | 66/221 (29.9) | 34/117 (29.1) | 32/104 (30.8) | 0.7817 |
| FLT3-ITD low ratio, NPM1 + | 15/221 (6.8) | 10/117 (8.5) | 5/104 (4.8) | 0.2700 |
| FLT3-ITD high ratio, NPM1 + | 31/221 (14) | 16/117 (13.7) | 15/104 (14.4) | 0.8730 |
wt, wild type; ICE, standard idarubicin-cytarabine-etoposide chemotherapy; sHD, sequential high dose chemotherapy.